The Biohazardous Agent Reference Document (BARD) is a general guidance resource that reviews and summarizes the nature of a pathogen or biotoxin, and offers safety requirements for work with the agent

in the laboratory. The BARD may replace the formal SOPs used in conjunction with some IBC registrations.

The BARD is provided as an additional guidance tool, and is not a substitute for a risk assessment, biosafety training, lab-specific training, or a formal [IBC master protocol registration](https://www.uvm.edu/rpo/biosafety-oversight). This document should be readily available in the laboratory, and it is the responsibility of the Laboratory Supervisor or Principal Investigator to ensure that all personnel have read, understood, and signed the document. The BARD is for informational purposes only, and is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Please consult a health care provider for any medical questions or concerns.

**INSTRUCTIONS**

1. **Review the information contained in this document.**
2. **Add any necessary information that is specific to your work in the laboratory (such as strain-specific information). Please be sure that the track changes function is turned on to indicate any changes that you make.**
3. **Instruct all personnel to review the BARD and sign the last page, indicating that they have**

**read and understood the information.**

1. **Submit the BARD along with your IBC master protocol registration, amendment, or continuing review.**

|  |  |
| --- | --- |
| **Characteristics** | |
| ***Morphology*** | Member of the Flaviviridae family, enveloped virus. |
| ***Strain Specific***  ***Characteristics*** |  |

|  |  |
| --- | --- |
| **health hazards** | |
| ***Host Range*** | Humans and non-human primates |
| ***Modes of Transmission*** | Blood borne, bite from infected *Aedes* mosquito, perinatal, in utero, sexual contact, contact with non-intact skin or mucous membranes |
| ***Signs and Symptoms*** | Mostly asymptomatic, but may present with: fever, rash, muscle and/or joint pain, conjunctivitis, headache |
| ***Infectious Dose*** | Unknown |
| ***Incubation Period*** | 3 – 12 days |

|  |  |
| --- | --- |
| **Medical precautions / treatment** | |
| ***Prophylaxis*** | None available |
| ***Vaccines*** | None available |
| ***Treatment*** | Symptomatic: fever reduction, anti-histamines, pain relief |
| ***Surveillance*** | Monitor for symptoms and test using serology, RT-PCR, or nucleic acid testing from blood or urine sample |
| ***UVM IBC Requirements*** | Report any exposures or signs and symptoms to your supervisor |
| ***Additional Medical Precautions*** | Women who are pregnant or planning on becoming pregnant should be aware that pregnant women infected with Zika can transmit the virus to their fetus, which can result in severe birth defects. Avoid contact with mosquitoes to prevent spreading the virus. |

|  |  |
| --- | --- |
| **laboratory hazards** | |
| ***Laboratory Acquired Infections*** | Accidental infection has occurred in laboratory personnel |
| ***Sources*** | Infected mosquitos, human or animal blood, body fluids, or tissues, laboratory cultures. |

|  |  |
| --- | --- |
| **Containment Requirements** | |
| ***BSL - 2*** | Manipulation of known or potentially infected clinical samples and cell cultures of laboratory adapted strains (RG2) |
| ***BSL - 3*** |  |
| ***ABSL - 2*** | Work with animals infected with risk group 2 strains |
| ***ABSL - 3*** |  |
| ***Aerosol generating activities*** | Centrifugation, homogenizing, vortexing or stirring, changing of animal cages, animal surgeries, cell sorting, pipetting, pouring liquids, sonicating, loading syringes |
| ***Primary containment device (BSC)*** | Use for aerosol-generating activities, large volumes, or high concentrations |

|  |  |
| --- | --- |
| **exposure procedures** | |
| ***Mucous membranes*** | Flush eyes, mouth or nose for 15 minutes at eyewash station. |
| ***Other exposures*** | Wash area with soap and water for 15 minutes |
| ***Medical Follow-Up*** | Contact UVMMC Infectious Disease Dept. directly at **(802) 847-2700** for immediate assistance. Bring this document with you if seeking medical care. |
| ***Reporting*** | Report all exposures or near misses to:   1. Your immediate Supervisor 2. The UVM Biosafety Officer at **(802) 777-9471** and Risk Management at **6-3242** 3. Risk Management and Safety; <https://www.uvm.edu/riskmanagement/incident-claim-reporting-procedures> |

|  |  |
| --- | --- |
| **Personal protective equipment (PPE)** | |
| ***Minimum PPE Requirements*** | Nitrile gloves, closed toed shoes, lab coat, appropriate eye/face protection |
| ***Additional Precautions***  ***(Risk assessment dependent)*** | Sharps use strictly limited. |

|  |  |
| --- | --- |
| **Viability** | |
| ***Disinfection*** | Susceptible to: 10% bleach, 2% glutaraldehyde, 2% paraformaldehyde, or 70% ethanol with a 10 minute contact time |
| ***Inactivation*** | Inactivated by heat >60°C, and pH of <4 or >11 |
| ***Survival Outside Host*** | Unknown |

|  |  |
| --- | --- |
| **Spill clean up procedures** | |
| ***Small Spill*** | Notify others working in the lab. Allow aerosols to settle. Don appropriate PPE. Cover area of the spill with paper towels and apply approved disinfectant, working from the perimeter towards the center. Allow 30 minutes of contact time before clean up and disposal. Dispose in double biowaste bags and biobox. |
| ***Large Spill*** | **Inside of a lab:** Call UVM Service Operations at 656-2560 and press option 1 to speak to a dispatcher. Ask them to page Risk Management and Safety.  **Outside of a lab:** Pull the nearest fire alarm and evacuate the building. Wait out front of the building for emergency responders to arrive. |

|  |
| --- |
| **Student / Employee Name SIGNATURE DATE** |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |

***Biosafety Review:***

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Jeff LaBossiere, Biological Safety Officer

|  |  |
| --- | --- |
| **References** | |
| Emerging Infectious Disease | <https://wwwnc.cdc.gov/eid/article/22/9/16-0664_article> |
| BMBL | <https://www.cdc.gov/biosafety/publications/bmbl5/> |
| CDC Guidelines | <https://www.cdc.gov/zika/laboratories/index.html> |
| OSHA Fact Sheet | <https://www.osha.gov/Publications/OSHA3917.pdf> |

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Date